Biotechnology company Moderna (NASDAQ:MRNA) is mulling a $130 price per COVID-19 dose in the U.S., according to Reuters.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The development comes as the process of procuring and distributing vaccines transitions from the government to commercial market dynamics. The previously declared COVID-19 pandemic emergency is about to expire in May.
The company had received nearly $1.7 billion in funding for the development of the vaccine and raked in nearly $18 billion from its sales last year. Nonetheless, contributions from COVID-19 vaccine sales to its top line have seen a decline.
Overall, the Street has a $222.86 consensus price target on MRNA implying a hefty 44.2% potential upside in the stock. That’s after a 13.7% drop in the share price since the beginning of 2023.
Read full Disclosure